Abstract
Vertebral fractures are believed to be important predictors for future vertebral and other fractures, leading to at least a 4- to 5-fold increase in the risk of subsequent fractures. However, little is known about their associated near-term costs. The purpose of this study was to quantify the subsequent fracture and cost outcomes emanating from patients with an incident vertebral fracture. A probabilistic decision analysis model was developed to estimate the expected cost of all subsequent fractures. We ran Kaplan-Meier time-to-event models on placebo patients in risedronate’s pivotal phase III clinical trial data to determine the cumulative incidence or probabilities of all fractures within one year of an incident vertebral fracture. Unit costs for health care payers in the USA and Sweden for vertebral, hip, other, and forearm/wrist fractures were multiplied by fracture probabilities to generate the expected costs of new fractures within one year of incident vertebral fractures. Our analysis found that that 26.1% of vertebral fracture patients with a mean age of 74 years refractured within 1 year (vertebral 17.4%; hip 3.6%; “other” 3.5%; forearm/wrist 1.6%). The calculated medical costs for those patients who refracture within 1 year was $5906 and €3670 for the USA and Sweden, respectively, while the weighted average cost across all patients (refracture and non-fracture) within a year of their incident fracture was $1541 (USA) and €958 (Sweden). These results suggest that therapies with proven, rapid efficacy may offer important economic value to healthcare payers, providers and patients.
Similar content being viewed by others
References
Ross PD, Davis JW, Epstein RS, Wasnich RD (1991) Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Int Med 114:919–923
Ross PD, Genant HK, Davis JW, Miller PD, Wasnich RD (1993) Predicting vertebral fracture incidence from prevalent fractures and bone mass density among non-black, osteoporotic women. Osteoporos Int 3:120–126
Black DM, Arden NK, Palermo L, Pearson M, Cummings SR (1999) Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. J Bone Miner Res 14:821–828
Kotowicz M, Melton LJ, Cooper C, Atkinson EJ, O’Fallon WM, Riggs BL (1994) Risk of hip fracture in women with vertebral fracture. J Bone Miner Res 5:599–605
Johnell O, Kanis JA, Oden A, Sernbo I et al. (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int 15:175–179.
Melton LJ, Atkinson EJ, Cooper C, O’Fallon W, Riggs BL (1999) Vertebral fractures predict subsequent fractures. Osteoporos Int 10:214–221
Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739
van Staa TP, Leufkens HG, Cooper C (2002) Does a fracture at one site predict later fractures at other sites? A British cohort study. Osteoporos Int 13:624–629
Cooper C, Atkinson EJ, O’Fallon W, Melton LJ (1992) Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota: 1985–1989. J Bone Miner Res 7:221–227
Clark AP, Schuttinga JA (1992) Targeted estrogen/progestogen replacement therapy for osteoporosis: calculation of health care cost savings. Osteoporos Int 2:195–200
Gehlbach SH, Bigelow C, Heimisdottir M, May S, Walker M, Kirkwood JR (2000) Recognition of vertebral fracture in a clinical setting. Osteoporos Int 11:577–582
Burge RT, Puleo E, Gehlbach S, Worley D, Klar J (2002) Inpatient hospital and post-acute care for vertebral fractures in women. Value-In-Health 5:301–311
Gehlbach SH, Burge RT, Puleo E, Klar J (2003) Hospital care of osteoporosis-related vertebral fractures. Osteoporos Int 14:53–60
Ray NF, Chan JK, Thamer M, Melton LJ (1997) Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 12:24–35
Phillips S, Fox N, Jacobs J, Wright W (1988) The Direct medical costs of osteoporosis for American women aged 45 and older, 1986. Bone 9:271–279
Chrischilles E, Shireman T, Wallace R (1994) Costs and health effects of osteoporotic fractures. Bone 15:377–386
US Congress Office of Technical Assistance (1994) Hip fracture outcomes in people age fifty and over: background paper. US Government Printing Office, Washington, D.C.
Decision Analysis by TreeAge (DATA), Version 3.5.4. TreeAge Software, Inc. Williamstown, Mass., USA
Harris ST, Watts NB, Genant HK et al. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 280:2077–2082
Reginster J, Minne HW, Sorensen OH et al. (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91
McClung MR, Geusens P, Miller PD et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333–340
Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285:320–323
National Osteoporosis Foundation (1998) Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effective analysis. Osteoporos Int Supplement 4:s1–s88
Nationwide Inpatient Sample, Release 6 (1997) Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality, Rockville, Maryland, USA
Hoerger T, Downs K, Lakshmanan M et al. (1999) Healthcare use among US women aged 45 and older: total costs and costs for selected postmenopausal health risks. J Women’s Health Gender-Based Med 8:1077–1089
Jacobsen SJ, Cooper C, Gottlieb MS et al. (1992) Hospitalization with vertebral fracture among the aged: a national population-based study, 1986–1989. Epidemiology 3:515–518
Ankjaer-Jensen A, Johnell O (1996) Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Osteoporos Int 6:265–275
Cooper C, O’Neill T, Silman AJ (1993) European Vertebral Osteoporosis Study Group. The epidemiology of vertebral fractures. Bone 14:S89–97
Holbrook TL et al. (1984) The frequency of occurrence, impact, and cost of selected musculoskeletal conditions in the US. American Academy of Orthopedic Surgeons, Chicago
Zethraeus N, Strömberg L, Jönsson B, Svensson O, Öhlén G (1997) The cost of a hip fracture. Estimates for 1709 patients in Sweden. Acta Orthop Scand 68:13–17
Zethraeus N, Borgström F, Johnell O, Kanis J, Önnby K, Jönsson B (2002) Costs and quality of life associated with osteoporosis related fractures—results from a Swedish survey. SSE/EFI Working Paper Series in Economics and Finance, No 512, October
Gabriel SE, Tosteson ANA, Leibson CL et al. (2002) Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 13:323–330
De Laet C, van Hout BA, Burger H et al. (1999) Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study. Osteoporos Int 10:66–72
Tosteson ANA, Gabriel SE, Grove MR et al. (2001) Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 12:1042–1049
Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, De Laet C, Jonsson B (2004) The risk of vertebral fractures in Sweden. Osteoporos Int 15:20–26
Acknowledgements
This study was supported by the Alliance for Better Bone Health (Aventis Pharma and Procter & Gamble Pharmaceuticals).
Conflict of interest:
No information supplied.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lindsay, R., Burge, R.T. & Strauss, D.M. One year outcomes and costs following a vertebral fracture. Osteoporos Int 16, 78–85 (2005). https://doi.org/10.1007/s00198-004-1646-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-004-1646-x